Previous 10 | Next 10 |
home / stock / kaltf / kaltf news
SAN FRANCISCO and TEL AVIV, Israel, June 21, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KALY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it has granted stock options on June 19, 2019 to the directors of the Company. The stock option...
SAN FRANCISCO and TEL AVIV, Israel, June 21, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced changes to the Company’s Board of Directors (the " Board "). Mr. Robin “Rob” Hutchison...
SAN FRANCISCO and TEL AVIV, Israel, June 18, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced that it has invented a novel first-in-class cannabinoid molecule, designated KAL-1816 , that strongly and ...
Kalytera Therapeutics ( OTCQB:KALTF ): Q1 GAAP EPS of -$0.021. More news on: Kalytera Therapeutics, Inc., Earnings news and commentary, Energy stocks news, , Read more ...
SAN FRANCISCO and TEL AVIV, Israel, May 31, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today reported financial results for the first quarter of 2019. (All dollars U.S. unless otherwise noted.) “Since ...
SAN FRANCISCO and TEL AVIV, ISRAEL, May 29, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the "Company" or "Kalytera") today announced that it has filed a provisional patent application with the United States Patent and Trademark Office ...
SAN FRANCISCO and TEL AVIV, Israel, May 28, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") today announced new laboratory findings demonstrating that cannabidiol (“ CBD ”) acts through a distinct biolo...
SAN FRANCISCO and TEL AVIV, Israel, May 21, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX VENTURE: KLY and OTCQB: KALTF) (the " Company " or " Kalytera ") has engaged Echelon Wealth Partners to determine the value, on a risk-adjusted basis, of its cannabidiol (" CBD ") therapeut...
STATnews reports that the rapidly growing cannabidiol (CBD) industry, expected to balloon to over $1.3B in three years, is creating headaches for lawmakers and the FDA. More news on: GW Pharmaceuticals plc, ETFMG Alternative Harvest ETF, Global X Fertilizers/Potash ETF, Healthcare stocks...
Not for distribution to U.S. Newswire Services or for dissemination in the United States. Any failure to comply with this restriction may constitute a violation of U.S. Securities laws. SAN FRANCISCO and TEL AVIV, Israel, May 14, 2019 (GLOBE NEWSWIRE) -- Kalytera Therapeutics, Inc. (TSX...
News, Short Squeeze, Breakout and More Instantly...
Kalytera Therapeutics Company Name:
KALTF Stock Symbol:
OTCMKTS Market:
Kalytera Therapeutics Website:
SAN FRANCISCO, CA and TORONTO, ON , Feb. 22, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that it has received comments from the Australian Human Research Ethics Committee (the “...
SAN FRANCISCO, CA and TORONTO, ON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the " Company " or " Claritas ") today announced that the Australian Human Research Ethics Committee (HREC) will meet on February 16 th to...
SAN FRANCISCO, CA and TORONTO, ON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Claritas Pharmaceuticals, Inc. (TSX VENTURE: CLAS and OTC: KALTF) (the “ Company ” or “ Claritas ”) today announced revised, improved pricing for the initial tranche of funds that the Co...